A rational design strategy and validation for protease-resistant fusion-inhibitor antiviral peptides
Year: 2026
Type: preprint
Abstract: Peptide-based fusion inhibitors are promising pharmaceuticals in the fight against enveloped viruses relying on membrane fusion for host infection. However, peptide therapeutic applications have long been hindered by their poor stability in vivo . Here, we discovered that peptide inhibitors with the wildtype sequence of the heptad repeat 2 (HR2) domain of the SARS-CoV-2 spike protein are efficiently cleaved by Transmembrane Protease, Serine 2 (TMPRSS2), a key protease involved in the SARS-CoV-2 virus-cell fusion pathway. We then identified the corresponding cleavage sites and designed three protease-resistant peptides using ranking based on deep mutational scanning and natural occurrence. The three candidates all exhibit inhibitory activity in a cell-cell fusion assay. A high-resolution cryo-EM structure of the top candidate, HR2-NHN, bound to its HR1 target reveals the molecular basis for its potent activity. The top candidate of the cell-based screening assay showed significantly improved efficacy relative to the wildtype peptide when administered at different times before infection in both an authentic virus-cell infection assay and a mouse assay. More broadly, our results suggest that the design strategies for protease-resistant peptides could be applied to a broad spectrum of other enveloped viruses and pave the way for the development of safe, prophylactic antivirals that can be administered before exposure.
Authors: Kailu Yang, Chuchu Wang, Francesco Topi, Serena Muratcioglu, Ravi Kant, Tomas Strandin, Yih Tyng Bong, Lauri Kareinen, Sanna Maki, Saber H. Saber, Tobias Binder, Tarja Sironen, Subu Subramanian, K. Ian White, Richard A. Pfuetzner, Luis Esquivies, Olli Vapalahti, Merja Joensuu, John Kuriyan, Jussi Hepojoki, Giuseppe Balistreri, Axel T. Brunger
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7213314809